Review

The Role of Immune Checkpoint Blockade in Uveal Melanoma

Anja Wessely 1, Theresa Steeb 1, Michael Erdmann 1, Lucie Heinzerling 1, Julio Vera 1, Max Schlaak 2, Carola Berking 1 and Markus Vincent Heppt 1,*

1 Department of Dermatology, Universitätsklinikum Erlangen, Friedrich Alexander University, Ulmenweg 18, 91054 Erlangen, Germany; anja.wessely@uk-erlangen.de (A.W.); theresa.steeb@uk-erlangen.de (T.S.); michael.erdmann@uk-erlangen.de (M.E.); lucie.heinzerling@uk-erlangen.de (L.H.); julio.vera-gonzalez@uk-erlangen.de (J.V.); carola.berking@uk-erlangen.de (C.B.)

2 Department of Dermatology and Allergy, University Hospital, LMU Munich, Frauenlobstr. 9-11, 80337 Munich, Germany; max.schlaak@med.uni-muenchen.de

* Correspondence: markus.heppt@uk-erlangen.de; Tel.: +49-9131-85-35747

Received: 18 December 2019; Accepted: 27 January 2020; Published: 29 January 2020

Abstract: Uveal melanoma (UM) represents the most common intraocular malignancy in adults and accounts for about 5% of all melanomas. Primary disease can be effectively controlled by several local therapy options, but UM has a high potential for metastatic spread, especially to the liver. Despite its clinical and genetic heterogeneity, therapy of metastatic UM has largely been adopted from cutaneous melanoma (CM) with discouraging results until now. The introduction of antibodies targeting CTLA-4 and PD-1 for immune checkpoint blockade (ICB) has revolutionized the field of cancer therapy and has achieved pioneering results in metastatic CM. Thus, expectations were high that patients with metastatic UM would also benefit from these new therapy options. This review provides a comprehensive and up-to-date overview on the role of ICB in UM. We give a summary of UM biology, its clinical features, and how it differs from CM. The results of several studies that have been investigating ICB in metastatic UM are presented. We discuss possible reasons for the lack of efficacy of ICB in UM compared to CM, highlight the pitfalls of ICB in this cancer entity, and explain why other immune-modulating therapies could still be an option for future UM therapies.

Keywords: uveal melanoma; ocular melanoma; immune checkpoint blockade; CTLA-4; cytotoxic T lymphocyte-associated antigen; ipilimumab; PD-1; programmed death 1; pembrolizumab; nivolumab

1. Introduction

Uveal melanoma (UM) represents the most common ocular malignancy in adults. About 85% to 90% of the primary tumors arise from melanocytes residing in the choroid, the pigmented layer of the eyeball that also contains blood vessels [1,2], and less frequently from the ciliary body or iris of the eye where melanocytes are also present [3]. With an incidence of 4–7 cases per million in Europe, it is much rarer than cutaneous melanoma (CM) [4]. Several factors have been associated with an increased risk of developing UM. These include the presence of choroidal or cutaneous nevi [5], fair skin, light eye color [6], oculodermal melanocytosis [7,8], inactivating mutations of the tumor-suppressor BRCA1-associated protein 1 (BAP1) [9,10], and exposure to ultraviolet (UV) radiation [11].

1.1. Cutaneous vs. Uveal Melanoma: Genetic Differences and Implications for Prognosis

Although UM and CM both arise from melanocytes and share similar risk factors, these melanoma subtypes substantially differ biologically and clinically [5]. Similar to other cancer entities that are associated with the exposure to environmental carcinogens such as nonsmall cell lung cancer (NSCLC),
CM has an extremely high mutational burden with up to 100 mutations per megabase [12,13]. Despite this huge number, a few typical driver mutations are found in the majority of CM tissue samples that affect members of the BRAF-MEK-ERK signaling cascade. About 40% to 50% harbor mutations in the BRAF gene coding for v-Raf murine sarcoma viral oncogene homolog, and about 20% harbor mutations in the NRAS gene coding for neuroblastoma rat sarcoma viral oncogene homolog [14–17]. Both activating BRAF and NRAS mutations lead to a constitutive activation of the mitogen-activated protein kinase (MAPK) signaling pathway that promotes proliferation and survival, and thereby contribute to cancer formation and progression [18,19].

In contrast to CM, the number of mutations in UM is extremely low [20], and interestingly, typical CM driver mutations are not present in UM and vice versa. Instead of BRAF and NRAS mutations, which are almost never observed in UM [21,22], more than 80% of all UM harbor mutations in the genes encoding the guanine nucleotide-binding proteins Q polypeptide (GNAQ) and α11 (GNA11) [21,22]. GNAQ and the closely related GNA11 encode Gα subunits of heterotrimeric G-proteins that interact with G-protein-coupled receptors. In about 90% of all cases, codon 209 [23] located in the Ras-like GTPase domain of the proteins is affected [24], and most commonly, glutamine is substituted by leucine (Q209L). This blocks the GTPase activity of the enzyme, resulting in a constantly bound GTP and thus a constitutive activation of the PLCβ/PKC pathway and downstream RAF-MEK-ERK signaling [21,22,25].

Besides, other downstream pathways as Trio-Rho-Rac and YAP-Hippo get activated by mutated Gα proteins [26]. A high PI3K-Akt-mTOR activity is also frequently observed in UM [27]; however, this seems to be the result of a phosphatase and tensin homolog (PTEN) expression loss [28], rather than due to mutated Gα proteins [28,29]. Other driver mutations in UM are by far less frequently detected and involve CYSLTR2 encoding the G-protein-coupled cysteinyl leukotriene receptor 2 and PLCB4 coding for phospholipase C β4, which act immediately upstream and downstream of GNAQ/11 in the signal transduction cascade [20,30,31].

Inactivating mutations in BAP1 are present in about 40% to 47% of UM primary tumors and 80% of UM metastases [32]. BAP1 is a tumor suppressor involved in the repair of DNA double strand breaks [33], and about 8% of UM patients carry BAP1 germline mutations leading to a loss of function [34]. Mutations in genes coding for splicing factor 3B, subunit 1 (SF3B1), which is required for RNA splicing, and the eukaryotic translation initiation factor 1A, x-linked (EIF1AX), are present in 29% and 48% [35–37], respectively. Commonly observed chromosomal aberrations in primary UM include monosomy of chromosome 3 and loss of chromosome 1p, 6q, and 8p, as well as amplifications of chromosome 1q, 6p, and 8q [38–42]. These alterations also decisively affect the patient’s prognosis.

1.2. Uveal Melanoma: Therapy and Prognosis

Several treatment approaches for primary UM are suitable to achieve sufficient control over local tumor growth and in most cases even preserve the vision of the affected eye [43,44]. These options for the primary tumor involve brachytherapy, external beam radiotherapy, photon-based radiation, or surgical approaches like local resection and enucleation of the affected eye [44–46]. However, up to 50% of the patients develop distant metastases [47], and unlike CM, UM primarily metastasizes to the liver [48]. The reasons for this selective behavior have not been fully elucidated yet. An enrichment of local growth factors, chemokines, and adhesion molecules, a slow blood flow, and the presence of proangiogenic tumor-associated macrophages (TAMs) have been discussed as factors that facilitate the homing, extravasation, and establishment of UM metastases in the liver. The slow blood flow in the hepatic sinusoids, together with the expression of vascular cell adhesion molecule-1 (VCAM-1) on endothelial cells, can promote the trapping of circulating UM cells in the liver [49]. Furthermore, the hepatic microenvironment is rich in locally produced growth factors such as insulin-like growth factor-1 (IGF-1), hepatic growth factor (HGF), and chemokines—such as CXCL12, which may contribute to homing and metastasis formation [50] and the receptors CXCR4 and c-Met, which bind to CXCL12 and HGF, respectively—are widely expressed in UM cells [51,52]. Thus, this interaction of UM cells and the hepatic microenvironment likely contributes to the establishment of hepatic metastases as UM
primary tumors expressing high levels of c-Met are associated with a higher risk for developing liver metastases [52].

Despite the tremendous advances in the therapy of advanced-stage CM in the last decade, which have been highlighted in several systematic reviews [53,54], the prognosis of metastatic UM has not changed and is still almost as poor as 30 years ago [55]. Five-year median overall survival (OS) rates for primary UM are around 80% [55]. However, these rates dramatically drop after diagnosis of metastatic disease to a median OS of about 13.4 months [56] and to a two-year OS of only 8% [46]. The presence of certain genetic aberrations has an impact on the clinical outcome and prognosis of UM in general [30,57]. A poor prognosis has been associated with monosomy 3 [58,59], mutations in the BAP1 gene, which is also located on chromosome 3p21.3 [60], and chromosome 8q amplifications [61]. Metastatic spread of UM occurs more often in tumors harboring GNA11 than GNAQ mutations [62,63], and SF3B1 mutations are associated with an intermediate risk of metastases and the onset of late-occurring metastases [64]. Among these aberrations, monosomy 3 seems to be the strongest predictor for disease progression [58]. On the other hand, the presence of EIFAX1 mutations [64] and chromosome 6p amplifications [59,61] are associated with a better prognosis. Besides, four molecularly different UM subsets can be defined, which are associated with different clinical outcomes [30].

In the metastatic stage, UM therapy has largely been adopted from CM. Once metastases are present, the disease course is often aggressive, and the prognosis remains dismal. A variety of local liver-directed treatment options have been investigated in clinical trials, but most of them did not result in a better survival in metastatic disease [65,66]. The frequently occurring GNAQ and GNA11 mutations that lead to a constitutive activity of the MAPK signaling pathway [21,22] provided the rationale for the use of small molecule inhibitors targeting the downstream kinases. Several inhibitors targeting MEK have already been developed and with trametinib, cobimetinib, and binimetinib, and three of them have been approved for metastatic BRAF-mutated CM in combination with a BRAF inhibitor [67–69]. However, a recent systematic review showed that UM is little responsive to MEK inhibition regardless of the inhibiting agent and combination partner [70]. For example, the potentially promising combination of binimetinib with the PKC inhibitor sotrastaurin showed no clinical efficacy, but a high number of patients developed severe adverse events, resulting in the termination of the respective phase Ib/II clinical trial [71]. The MEK inhibitor selumetinib showed promising results in a phase II study compared to chemotherapy, with a response rate of 14% [72]. Thus, the expectations were high that similar results would be achieved in the SUMIT trial, a prospective double-blind phase III study investigating selumetinib plus dacarbazine versus dacarbazine alone [73]. Unfortunately, disappointing results were observed, as only 3% of the patients responded, and the progression-free survival (PFS) could not be significantly prolonged by the therapy. Additionally, metastatic UM patients who received the multikinase inhibitor sorafenib have shown a significantly longer median PFS compared to placebo in the randomized phase II STREAM study. However, the median OS was not different between both groups (13 months with sorafenib vs. 12.2 months with placebo) [74]. Other targeted treatment approaches have also shown no promising results, as recently reviewed in [75,76].

In contrast to MEK inhibitors, immune checkpoint blockade (ICB) with programmed death 1 (PD-1) inhibitors and the anti-cytotoxic T lymphocyte-associated antigen (CTLA-4) antibody ipilimumab has shown strong survival benefits in recent years in CM [77–80]. However, patients with UM have been widely excluded from most of the pivotal trials. Here, we provide a comprehensive and up-to-date overview of the role of ICB in UM.

2. Immune Checkpoints in Cancer Therapy

The immune response is a delicate process that needs to be balanced carefully in order to fulfill its function in the defense against pathogens on the one hand and to avoid massive damage of healthy tissue on the other hand. Several immune checkpoints help to control autoimmunity and maintain self-tolerance. Cytotoxic CD8+ T lymphocytes (CTLs) are able to identify and destroy infected cells as well as tumor cells by recognizing epitopes of antigens that are presented by human leukocyte
antigen (HLA) class I molecules on the cell surface and thereby play an essential role in maintaining the integrity of the body [81].

The anti-CTLA-4 monoclonal antibody ipilimumab was the first immune checkpoint inhibitor approved for therapy of metastatic CM by the US Food and Drug Administration (FDA) in 2011 [82]. CTLA-4 is a critical negative regulator of the T cell response. In general, T cell activation requires the transduction of two signals [83]: Signal 1 involves the interaction of a foreign peptide or mutated self-antigen bound to the major histocompatibility complex (MHC) on antigen-presenting cells (APCs) and the T cell receptor (TCR) on T cells. Additionally, a second antigen-independent signal has to be transduced by costimulatory B7 proteins CD80 (B7.1) and CD86 (B7.2) located on APCs that interact with the co-receptor CD28 on T cells [83]. Only both signals can fully activate T cells, which includes their clonal expansion and the expression of effector cytokines. CTLA-4 is expressed on both activated T cells and regulatory T cells (Tregs). It is constitutively internalized; thus, about 90% of all CTLA-4 is found in intracellular vesicles unless its surface expression is upregulated due to stimulatory signals [84]. CTLA-4 binds to the costimulatory ligands CD80 and CD86 with a higher affinity than CD28 and thereby prevents their interaction with CD28 and subsequent T cell activation [85]. Additionally, this interaction also increases the expression of indoleamine 2,3-dioxygenase (IDO) in dendritic cells (DCs) [86]. IDO mediates immunosuppressive effects by converting the amino acid tryptophan to kynurenine, a metabolite that directly induces apoptosis in T cells. Furthermore, IDO-mediated tryptophan depletion impairs T cell function by leading to cell cycle arrest and anergy [87]. CTLA-4 binding to its ligands also leads to the removal of CD80/86 from the APC surface by a mechanism termed trans-endocytosis and further impairs T cell activation [88]. Thus, the number of activated T cells is controlled. CTLA-4 plays an important role in the maintenance of self-tolerance and the control of autoreactive T cells, as shown in studies with knockout mice [89]. The inhibitory effect of CTLA-4 can be overcome either by upregulating CD80/86 on APCs—which occurs physiologically in response to inflammatory stimuli in vivo—or therapeutically by administering antibodies targeting CTLA-4. These prevent the interaction with CD80/86 on APCs and additionally lead to the elimination of immunosuppressive Tregs via both direct cytotoxicity and antibody-dependent cell cytotoxicity in the tumor [85] and thereby boost T cell activation and the initiation of effector T cells (Figure 1A).

A second immune checkpoint that is exploited for cancer therapy involves the PD-1–PD-L1 axis. The interaction of the receptor PD-1 and its ligands programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2) is an important mechanism to avoid tissue damage from autoreactive T cells and maintain the peripheral tolerance [90]. PD-L1 is constitutively expressed in low levels on the cell surface of nonhematopoietic cells as well as on T cells, B cells, macrophages, and DCs [90,91]. Mediated by proinflammatory cytokines such as interferon gamma (IFN-γ) and tumor necrosis factor-α (TNF-α) that are released by activated T cells, its expression is upregulated during inflammatory processes. PD-L1 binds to its receptor PD-1, which is widely expressed on T cells, B cells, and some myeloid cells [90]. When the TCR is simultaneously bound, the interaction of PD-L1 and PD-1 leads to the transduction of an inhibitory signal that blocks TCR signaling [91] by reducing PTEN phosphorylation, phosphoinositide 3-kinase (PI3K) inhibition [92], and MEK-ERK pathway activation [93]. This results in diminished T cell function due to reduced production of the T cell effector cytokines IFN-γ, TNF-α, and interleukin-2 (IL-2) and a decreased T cell proliferation and survival [94–96]. Thus, the PD-1–PD-L1 axis limits an extensive and too-long-lasting immune response that may damage healthy tissue. The second PD-1 ligand PD-L2 has been less extensively investigated yet. Its expression is limited to macrophages, DCs, mast cells, and B cells and can be induced by IL-4; however, the transcriptional regulation has not been fully elucidated yet [97]. In contrast to PD-L1, binding of PD-1 to PD-L2 suppresses the activation of T cells in lymphoid organs [98].
been detected in various tumor types on tumor cells, invading immune cells and endothelial cells [103]. Antibodies against PD-1 or its ligand PD-L1 are able to inhibit the PD-1-mediated transduction of inhibitory signals and prevent the inactivation of tumor-reactive immune cells. This strategy has been used successfully for the treatment of a variety of tumors including CM [77] (Figure 1B).

Figure 1. Molecular mechanism of immune checkpoints. (a) CTLA-4 is a critical negative regulator of the T cell response in the early activation phase of the adaptive immune response. It binds to the costimulatory ligands CD80 and CD86 on antigen-presenting cells with a higher affinity than CD28 and thereby prevents their interaction with CD28 and subsequent T cell activation. Anti-CTLA-4 antibodies block the interaction of CTLA-4 and CD80/86 and boost T cell activation and the anti-tumor response. (b) The PD-1–PD-L1 axis is an important mechanism to avoid tissue damage from autoreactive T cells and maintains the peripheral tolerance. Binding of PD-L1 to its receptor PD-1 blocks T cell receptor (TCR) signaling, resulting in limited T cell function. Antibodies targeting PD-1 or its ligand PD-L1 are able to inhibit their interaction and prevent the inactivation of tumor-reactive immune cells.
Tumor cells are capable of escaping T cells by exploiting the PD-1–PD-L1/PD-L2 axis to dampen the antitumoral immune response. PD-L1 can be expressed in high levels and on the majority of both tumor cells and tumor-infiltrating immune cells in several cancer entities like CM [77,99], NSCLC [100], epithelial ovarian cancer [101], and breast cancer [102]. Similarly, PD-L2 expression has also been detected in various tumor types on tumor cells, invading immune cells and endothelial cells [103]. Antibodies against PD-1 or its ligand PD-L1 are able to inhibit the PD-1-mediated transduction of inhibitory signals and prevent the inactivation of tumor-reactive immune cells. This strategy has been used successfully for the treatment of a variety of tumors including CM [77] (Figure 1B).

3. Studies Investigating Immune Checkpoint Blockade for UM Treatment

In the past, UM patients have been excluded from most trials investigating ICB for CM treatment. However, some prospective phase I and II trials have also included UM patients. An up-to-date summary of the most important pro- and retrospective analyses, dosage schemes, and study results are presented in the following overview (Table 1).
Table 1. Studies investigating immune checkpoint blockade for UM treatment.

| Author/Trial [Reference] | Design | Number of Evaluated (Enrolled) Patients | Intervention | Dosage ORR | PR | CR | PFS (Median) | OS (Median) | Severe AE > grade 3 |
|--------------------------|--------|----------------------------------------|--------------|-----------|----|----|--------------|-------------|---------------------|
| **Anti-CTLA-4 antibodies** |
| Ipilimumab |
| Rozeman 2019 SECIRA-UM [104] | Open-label, 3-armed, single-center phase Ib/Ib trial | 3 | Ipilimumab + RFA | 0.3 mg/kg | 0 | 0 | 0 | 2 mo. | n.r. | 1/3 (33%) * |
| | | 19 | Ipilimumab + RFA | 3 mg/kg | 0 | 0 | 0 | 2 mo. | 9.7 mo. | 6/19 (32%) * |
| | | 19 | Ipilimumab + RFA | 10 mg/kg | 0 | 0 | 0 | 2 mo. | 14.2 mo. | 10/19 (52%) * |
| Shaw 2012 [105] | EAP | 18 | Ipilimumab | 3 mg/kg | n.r. | n.r. | n.r. | 14.5 wks. (range 6 – 64) | n.r. | not clearly reported |
| Kelderman 2013/ WIN-O [106] | EAP | 22 | Ipilimumab | 3 mg/kg | 1/22 (4.5%) | 1/22 (4.5%) | 0 | 2.9 mo. (95% CI 2.3–3.3) | 5.2 mo. (95% CI 4.9–6.6) | 3/22 (13.6%) |
| Miao 2013 [107] | EAP | 82 (83) | Ipilimumab | 3 mg/kg | 4/82 (4.8%) | 4/82 (4.8%) | 0 | 3.6 mo. (95% CI 2.8–4.4) | 6.0 mo. (95% CI 4.3–7.7) | 3/82 (6%) |
| Zimmer 2015 [108] | Observational, prospective, open-label, uncontrolled, multicenter phase II trial | 53 | Ipilimumab | 3 mg/kg | 0 | 0 | 0 | 2.8 mo. (95% CI 2.5–2.9) | 6.8 mo. (95% CI 3.7–8.1) | 19/53 (36%) * |
| Jung 2017 [109] | NPP | 10 | Ipilimumab | 3 mg/kg | n.r. | n.r. | n.r. | 2.8 mo. | not reached | 0 |
| Piulats 2014/ GEMI [110] | Observational, prospective, open-label, single-arm phase II trial | 31 (32) | Ipilimumab | 10 mg/kg | 2/31 (6.5%) | 2/31 (6.5%) | 0 | n.r. | 9.8 mo. | 5/31 (16%) |
| Danielli 2012/ I-OMEAP [111] | EAP | 13 | Ipilimumab | 10 mg/kg | 0 | 0 | 0 | n.r. | 36 wks. (range 2–172+) | 3/13 (23%) |
| Fountain 2019 NCT01585194 [112] | Interventional, prospective, open-label, phase III trial | 10 | Ipilimumab (adjuvant setting) | 3 mg/kg (n = 3) | 10 mg/kg (n = 7) | n.r. | n.r. | n.r. | n.r. | n.r. | 1/10 (10%) |
| Luke 2013 [113] | Uncontrolled, multicenter, retrospective analysis | 39 | Ipilimumab | 3 mg/kg (n = 34) | 10 mg/kg (n = 5) | 2/39 (5.1%) | 1 (late) (2.6%) | 1/39 (2.6%) | n.r. | 9.6 mo. (95% CI 6.3–13.4) | 7/39 (17.9%) |
| Ichims 2017 [114] | Uncontrolled, single-center, retrospective cohort analysis | 37 | sequential TAC (temozolomide) + ICB (ipi, nivo or pembro) + systemic chemotherapy | 100 mg/m² (temozolomide), 3 mg/kg (ipi/nivo) 2 mg/kg (pembro) | ICB first-line: 3/14 (21.4%) | ICB second-line: 2/12 (16.7%) | Ipi: 1/22 (4.5%) | Pembrolizumab: 2/15 (13%) | Nivo: 1/4 (25%) | 9 mo. (95% CI 6.2–13.2) | 17.0 mo. (95% CI 12–26) | not clearly reported |
| **Tremelimumab** |
| Joshua 2015 [116] | Observational, prospective, open-label, multicenter phase II study | 11 | Tremelimumab | 15 mg/kg | 0 | 0 | 0 | 2.9 mo. (95% CI 2.8–3.0) | 12.8 mo. (95% CI 3.8–19.7) | not clearly reported |
Table 1. Cont.

| Study | Design | Treatment Arm 1 | Treatment Arm 2 | Nivolumab | Pembrolizumab | Combined ICB: anti-CTLA-4 + anti-PD-1 antibodies |
|-------|--------|----------------|-----------------|-----------|--------------|--------------------------------------------------|
|       |        | Anti-PD-1 antibodies |                 |           |              |                                                   |
|       |        | Nivolumab | Pembrolizumab |           |              |                                                   |
|       |        | Nivolumab | Pembrolizumab | 3 mg/kg | 2 mg/kg | 5 mg/kg (niv) + 3 mg/kg (ipi) |
|       |        |           |              |           |              |                                                   |
|       |        |           |              | 2/34 (5.8%) at 12 wks. | 2/34 (5.8%) | 2/34 (5.8%) |
|       |        |           |              | 0         | 0          | 0 |
|       |        |           |              | 2.3 mo. | 9.6 mo. | n.r. |
|       |        |           |              | 11 mo. (95% CI 7–15) | not clearly reported | not clearly reported |
|       |        |           |              | 1/12 (7.1%) | 1/12 (7.1%) | 0 |
|       |        |           |              | 10 wks. (range 4–105) | 60 wks. (range 5–105) | n.r. |
|       |        |           |              | 1/12 (7.1%) grade 4 hyper-glycemia | n.r. | n.r. |
|       |        |           |              | 2.3 mo. | 8.0 mo. | n.r. |
|       |        |           |              | 4.8 mo. | 9.9 mo. | n.r. |
|       |        |           |              | 3.7 mo. | 18.9 mo. | n.r. |
|       |        |           |              | 2.6 mo. (95% CI 1.2–2.8) | 7.7 mo. (95% CI 0.7–14.6) | n.r. |
|       |        |           |              | 3.8 mo. (95% CI 2.2–9.7) | not reached | n.r. |
|       |        |           |              | 3.0 mo. | 9.9 mo. | n.r. |
|       |        |           |              | 3.7 mo. | 18.9 mo. | n.r. |
|       |        |           |              | 2.6 mo. (95% CI 1.2–2.8) | 7.7 mo. (95% CI 0.7–14.6) | n.r. |
|       |        |           |              | 3.8 mo. (95% CI 2.2–9.7) | not reached | n.r. |
|       |        |           |              | 3.8 mo. (95% CI 2.2–9.7) | not reached | n.r. |
|       |        |           |              | 3.8 mo. (95% CI 2.2–9.7) | not reached | n.r. |
|       |        |           |              | 3.8 mo. (95% CI 2.2–9.7) | not reached | n.r. |
|       |        |           |              | 3.8 mo. (95% CI 2.2–9.7) | not reached | n.r. |
|       |        |           |              | 3.8 mo. (95% CI 2.2–9.7) | not reached | n.r. |
|       |        |           |              | 3.8 mo. (95% CI 2.2–9.7) | not reached | n.r. |
|       |        |           |              | 3.8 mo. (95% CI 2.2–9.7) | not reached | n.r. |
|       |        |           |              | 3.8 mo. (95% CI 2.2–9.7) | not reached | n.r. |
|       |        |           |              | 3.8 mo. (95% CI 2.2–9.7) | not reached | n.r. |
|       |        |           |              | 3.8 mo. (95% CI 2.2–9.7) | not reached | n.r. |
|       |        |           |              | 3.8 mo. (95% CI 2.2–9.7) | not reached | n.r. |
|       |        |           |              | 3.8 mo. (95% CI 2.2–9.7) | not reached | n.r. |
|       |        |           |              | 3.8 mo. (95% CI 2.2–9.7) | not reached | n.r. |
|       |        |           |              | 3.8 mo. (95% CI 2.2–9.7) | not reached | n.r. |
|       |        |           |              | 3.8 mo. (95% CI 2.2–9.7) | not reached | n.r. |
|       |        |           |              | 3.8 mo. (95% CI 2.2–9.7) | not reached | n.r. |
|       |        |           |              | 3.8 mo. (95% CI 2.2–9.7) | not reached | n.r. |
|       |        |           |              | 3.8 mo. (95% CI 2.2–9.7) | not reached | n.r. |
|       |        |           |              | 3.8 mo. (95% CI 2.2–9.7) | not reached | n.r. |
|       |        |           |              | 3.8 mo. (95% CI 2.2–9.7) | not reached | n.r. |
|       |        |           |              | 3.8 mo. (95% CI 2.2–9.7) | not reached | n.r. |
|       |        |           |              | 3.8 mo. (95% CI 2.2–9.7) | not reached | n.r. |
|       |        |           |              | 3.8 mo. (95% CI 2.2–9.7) | not reached | n.r. |
|       |        |           |              | 3.8 mo. (95% CI 2.2–9.7) | not reached | n.r. |
|       |        |           |              | 3.8 mo. (95% CI 2.2–9.7) | not reached | n.r. |
|       |        |           |              | 3.8 mo. (95% CI 2.2–9.7) | not reached | n.r. |
|       |        |           |              | 3.8 mo. (95% CI 2.2–9.7) | not reached | n.r. |
|       |        |           |              | 3.8 mo. (95% CI 2.2–9.7) | not reached | n.r. |
|       |        |           |              | 3.8 mo. (95% CI 2.2–9.7) | n.r. | n.r. |
|       |        |           |              | 3.8 mo. (95% CI 2.2–9.7) | not clearly reported | n.r. |
|       |        |           |              | 3.8 mo. (95% CI 2.2–9.7) | not clearly reported | n.r. |
Table 1. Cont.

| Study            | Approach                  | Treatment                                                                 | N | DCR | SRR | Median OS (95% CI) | HR 12 mos | HR 16 mos |
|------------------|---------------------------|----------------------------------------------------------------------------|---|-----|-----|--------------------|-----------|-----------|
| Heppt 2017 [129] | Uncontrolled, multicenter, retrospective analysis | Nivolumab/pembrolizumab + ipilimumab                                      | 12 (15) | 3 mg/kg (ipi) + 1 mg/kg (nivo), 3 mg/kg (nivo, maintenance) (n = 7) | 2/12 (16.7%) | 2/12 (16.7%) | 0 | 2.8 mos. | not reached | 4/15 (26.7%) * |
|                  |                           |                                                                            |   | 1 mg/kg (ipi) + 3 mg/kg (nivo), 3 mg/kg (nivo, maintenance) (n = 2) | | | | | | |
|                  |                           |                                                                            |   | 1 mg/kg (ipi) + 2 mg/kg (pembro), 2 mg/kg (pembro, maintenance) (n = 6) | | | | | | |
| Heppt 2019 [130] | Uncontrolled, multicenter retrospective analysis | Pembrolizumab monotherapy                                                  | 53 (54) | 2 mg/kg | 3/53 (5.7%) | 3/53 (5.7%) | 0 | 3.1 mos. | 14 mos. | 4/54 (7.4%) * |
|                  |                           |                                                                            |   | 3 mg/kg | 1/52 (1.1%) | 1/52 (1.1%) | 0 | 2.8 mos. | 10 mos. | 4/52 (12.5%) * |
| Karivedu 2019 [131] | Uncontrolled, single-center, retrospective analysis/case series | TACE + nivolumab + ipilimumab, TACE + nivolumab (maintenance)              | 8  | 3 mg/kg (ipi) + 1 mg/kg (nivo), 240 mg (nivo, maintenance) | 2/8 (25%) | 2/8 (25%) | 0 | n.r. | 14 mos. | 4/8 (50%) colitis; severity not clearly reported |

All studies investigated ICB in patients with metastatic melanoma; exception: Fountain 2019/ NCT01585194 (adjuvant ICB in patients with a high risk for developing metastases). *: Authors did not distinguish between grade 3 and 4 when reporting the severity of AEs. Abbreviations: CI = confidence interval; DCR = disease control rate; EAP = expanded access program; ICB = immune checkpoint blockade; ipi = ipilimumab; mo. = months; nivo = nivolumab; NPP = named patient program; n.r. = not reported; pembro = pembrolizumab; RFA = radiofrequency ablation; TAC = transarterial chemotherapy; TACE = transarterial chemoembolization; wks. = weeks.
3.1. CTLA4-Blocking Antibodies

3.1.1. Ipilimumab

The anti-CTLA-4 monoclonal antibody ipilimumab was the first immune checkpoint inhibitor approved for therapy of metastatic CM by the FDA in 2011 [82].

The prospective investigator-initiated SECIRA-UM trial investigated different dosages of ipilimumab combined with radiofrequency ablation (RFA) in 41 patients with UM and at least two liver metastases in a phase Ib/II trial [104]. No complete responses (CR) or partial responses (PR) were observed. Severe adverse events (AEs) were reported in 52% of the patients who had received the highest dosage (10 mg/kg), most frequently immune-related colitis. The frequency of grade 3 and 4 AEs was associated with a higher dosage of ipilimumab [104].

Five additional prospective studies with 185 patients in total investigated ipilimumab at a dose of 3 mg/kg body weight [105–109]. In the study published by Jung et al. [109], 10 UM patients (total n = 106 melanoma patients) were treated. The median PFS was 2.8 months (graphically determined based on the published time-to-event analyses), and it was unclear whether the median OS had been reached at the time of publication. Secondary outcomes were not reported; furthermore, the UM subgroup was poorly described [109]. In the other prospective studies that investigated this dosage scheme (3 mg/kg), overall response rates (ORR) ranged from 0% [108] to a sobering 4.8% [107]. The median PFS and OS were quite short, with a median PFS ranging from 2.8 months [108] to 3.6 months [107] and a median OS between 5.2 months [106] and 6.8 months [108]. The frequency of severe treatment-related AEs differed between the studies and ranged between 6% [107] and 36% [108].

Higher ipilimumab dosages of 10 mg/kg were investigated in three pro- and one retrospective analysis [110–113]. Interestingly, a prolonged median OS of up to 9.8 months was observed; however, the ORR did not differ from other trials investigating lower dosages. Median PFS was not determined in any of these four studies. Similar to the SECIRA-UM trial [104], the high dosage of ipilimumab was also associated with a higher number of severe AEs. Nine of the 10 study participants developed grade 3 AEs, and in one patient who participated in an adjuvant study, temporal arteritis resulted in persistent blindness [112].

Itchins et al. [114] reported the results of a single-center cohort analysis on 37 metastatic UM patients who received a sequential therapy with transarterial chemotherapy (TAC), ICB (predominantly ipilimumab), and a systemic chemotherapy. Although the ORR was comparably poor, this combined approach led to the longest median PFS (9 months) and OS (17 months) among all therapies investigating ipilimumab. However, interpreting these results may be problematic, as the authors did not distinguish between different ICB antibodies when reporting the outcomes [114].

Bol et al. [115] compared the efficacy of ipilimumab, pembrolizumab, and a combined therapy with ipilimumab and nivolumab in a retrospective population-based study including 86 patients. None of the 24 patients treated with ipilimumab responded to the therapy. The median PFS was 3.0 months and the median OS was 9.9 months [115].

3.1.2. Tremelimumab

Tremelimumab (CP 675206) is another monoclonal CTLA-4-targeting antibody. In a multicenter phase II trial published by Joshua et al. [116], 11 UM patients received 15 mg/kg tremelimumab. None of the patients achieved an objective response (CR or PR). The median PFS was 2.9 and the median OS was 12.8 months. Secondary outcomes were not clearly reported. The poor results regarding PFS and radiological response led to the withdrawal of the trial at the first interim stage [116].

Taken together, the anti-CTLA-4 antibodies ipilimumab and tremelimumab showed a poor efficacy on the one hand with poor response rates and short PFS and OS, and its use in an adjuvant setting also achieved only discouraging results. On the other hand, a significant number of patients developed severe AEs. These results highlight the low efficacy and high toxicity of these antibodies for the treatment of metastatic UM.
3.2. PD-1/PD-L1 Blocking Antibodies

3.2.1. Nivolumab

The PD-1 blocking antibody nivolumab was evaluated in one prospective phase II trial [117] and three retrospective analyses [118–120].

In the prospective CheckMate 172 trial [117], a subgroup of 75 UM patients with progressive disease after anti-CTLA-4 therapy was included, 34 of whom were evaluable for outcome analysis. Two PR were achieved in this subgroup (ORR 6%), and 15 patients (44%) had stable disease (SD) after a minimum follow-up of 1 year. The median OS was 11 months, thus better than the median OS for ipilimumab in this group of patients. Data on the UM subgroup regarding PFS or severe AEs were not reported [117].

Three other reports retrospectively evaluated the efficacy of nivolumab in a rather low number of patients [118–120]. ORR ranged from 0% [118] up to 25% [119]. The median PFS was not reported in [119] and was 2.3 months in the other studies, and the median OS ranged from 9.6 months [118] to about 14 months [120]. Remarkably, the studies reported by Tian et al. [119] and van der Kooij et al. [118] also included patients receiving pembrolizumab; however, the authors did not distinguish between both interventions when reporting the outcomes. In general, the patients tolerated the treatment well. Severe AEs were only reported for one patient who developed a grade 4 hyperglycemia due to ICB-related diabetes [120].

Altogether, in comparison with ipilimumab, patients receiving nivolumab achieved a similar median PFS but a longer median OS. The response rates varied from 0% up to a promising 25% in the retrospective analyses, whereas the ORR in the phase II trial was 5.8%, which is comparable to the results achieved with ipilimumab. However, the safety of nivolumab seems to be better than that of ipilimumab.

3.2.2. Pembrolizumab

The efficacy of pembrolizumab for the treatment of metastatic UM was evaluated in several expanded access programs (EAPs), retrospective analyses, and one phase II trial [115,121–125]. Kottschade et al. [121] and Karydis et al. [122] evaluated the efficacy of pembrolizumab in two EAPs including 10 and 25 patients, respectively. Kottschade et al. reported a high ORR of 37.5%; however, the number of enrolled and evaluated patients was relatively low. In contrast, Karydis et al. reported an ORR of only 8%. The median PFS were reported as 4 months (18 weeks) and 3 months (91 days), and the median OS was not reached in the study of Kottschade and not reported by Karydis. One patient developed severe AEs > grade 3. Recently, Johnson et al. published data on a small single-arm phase II study in five patients with metastatic UM (NCT02359851) [123]. One patient had a CR after receiving one dose, and two patients had a prolonged SD (20% response rate, 60% clinical benefit rate). However, these three patients had either no liver metastases or only small metastases. The median PFS was 11.0 months, which was almost three times longer than those achieved in the aforementioned EAPs. The median OS was not reached. Serious AEs > grade 3 were reported for one patient [123]. Rossi et al. [126] published the results of a prospective observational single-arm study evaluating the efficacy of pembrolizumab in 17 patients with metastatic UM. ORR was 11.7%, but no CR was achieved. The median PFS was 3.8 months, which is comparable to the results reported by Kottschade and Karydis [121,122]. Interestingly, patients with both liver and extrahepatic metastases had a longer median PFS than those with hepatic metastases only (8.4 vs. 3.1 months). No severe AEs > grade 3 were observed [126].

Additionally, three retrospective studies analyzed the efficacy of pembrolizumab and other anti-PD-1 and anti-PD-L1 antibodies [115,124,125]. In the publication of Bol et al. [115], the outcomes for each antibody were separately reported, whereas the other two publications did not clearly distinguish between the interventions. Bol et al. [115] compared the efficacy of pembrolizumab, ipilimumab, and a combined therapy with ipilimumab and nivolumab in a retrospective population-based study.
including 86 patients. ORR for pembrolizumab was 7%. The median PFS was 4.8 months and the median OS was 10.3 months [115]. Algazi et al. [124] published the results of a multicenter analysis including 56 metastatic UM patients who received either pembrolizumab, nivolumab or the anti-PD-L1 antibody atezolizumab. The median PFS was 2.6 months and the median OS was 7.7 months; however, the authors did not clearly distinguish between the interventions when reporting the outcomes. A PR was observed only in two patients who had received either nivolumab or pembrolizumab [124]. A second retrospective analysis published by Piperno-Neumann et al. [125] described the results of 21 metastatic UM patients who were treated with pembrolizumab or nivolumab. The median PFS was 3 months and thus similar to the one reported by Algazi et al. [125]. In general, the therapy was well tolerated by the patients as no serious AEs > grade 3 were reported in any of the three retrospective trials.

In summary, PD-1 blocking antibodies showed a better clinical efficacy in patients with metastatic UM regarding the median OS and a more favorable toxicity profile compared to CTLA-4 blocking antibodies. The ORR achieved with nivolumab and pembrolizumab varied extremely in different trials, which makes it difficult to evaluate the efficacy.

3.3. Combination Therapies/Combined ICB: CTLA-4 and PD-1 Blockade

Several studies have evaluated the effect of combined ICB in UM. A combination of nivolumab and ipilimumab was assessed in an EAP reported by Shoushtari et al. [127]. Sixty-four patients with metastatic melanoma, including a UM subgroup of six patients, were included. No objective responses were achieved in the UM subgroup. The median PFS for UM patients was 2.8 months. No data on OS or serious AEs were specifically reported for the UM subgroup [127]. Piulats et al. reported data of an interim analysis of the prospective phase II GEM1402 trial (NCT02626962) [128]. The ORR was 12%, the median PFS was 3.3 months, and median OS was 12.7 months. A high number of patients (54%) developed grade 3 and 4 AEs, and nine patients discontinued the treatment [128].

Besides, four retrospective analyses investigated the efficacy of combined treatment approaches. One analysis published by Heppt et al. [129] compared the efficacy of PD-1 monotherapy using pembrolizumab or nivolumab with a combined anti-PD-1 and anti-CTLA-4 therapy in 101 UM patients. The median PFS were 3.1, 2.8, and 2.8 months and the median OS were 14 months, 10 months and not reached for pembrolizumab, nivolumab, and combined ICB, respectively. The ORRs were 3% and 5.7% for nivolumab and pembrolizumab monotherapy, respectively, in contrast to 16.7% for the combinational approach; however, no CR was observed in any treatment subgroup. Severe AEs ≥ grade 3 were more frequent in the treatment arm receiving the combination therapy compared to those receiving anti-PD-1 monotherapy (26.7% vs. 7.4% or 12.5%) [129]. Another multicenter analysis evaluated the efficacy of two ICB treatment combinations in 64 metastatic UM patients [130]. The patients received nivolumab or pembrolizumab plus ipilimumab. The authors did not distinguish between both combinations when reporting the results. The ORR was 15.6%, the median PFS was 3.0 months, and the median OS was estimated to be 16.1 months. Similar response rates were reported by Piulats et al. 2018 [128] and Heppt et al. 2017 [129] for combined ICB in this cancer entity as mentioned above. A high number of patients developed severe ICB-related AEs of grade 3 (24 patients, 37.5%) and grade 4 (1 patient, 1.6%) [130]. Furthermore, Karivedu et al. [131] published a retrospective analysis of eight metastatic UM patients who were treated with transarterial chemoembolization (TACE) and a combined ICB with nivolumab and ipilimumab. The median OS was 14 months and the median PFS was not reported. Two patients (25%) achieved a PR. Four patients developed treatment-related colitis; however, the severity of the AEs was not clearly reported. [131]. In a retrospective population-based study, Bol et al. [115] evaluated the efficacy of a combined therapy with ipilimumab and nivolumab in 19 patients. The combined approach led to an ORR of 21.1%. The median PFS was 3.7 months and the median OS was 18.9 months [115].

Taken together, the longest median OS was achieved with combined ICB. The median PFS was around 3 months and comparable among the different studies and antibodies. The longest median
PFS of 9 months was achieved in a study investigating a treatment approach combining ICB, TAC, and systemic chemotherapy [114]. Throughout the studies, most of the responding patients achieved only a PR. Regarding safety, ipilimumab showed the most unfavorable toxicity profile as a high number of patients developed severe AEs > grade 3 but did not clinically benefit from this treatment. Thus, a combined ICB using PD-1- and CTLA-4-blocking antibodies seems to be the best option that is currently available for patients with metastatic UM.

4. ICB in Uveal Melanoma—Doomed to Fail?

The enormous success of ICB for the treatment of metastatic CM raised the expectations that metastatic UM patients would also benefit from the new therapy options. However, as presented above, the results were rather disappointing. Several reasons might explain the poor response rates of ICB in metastatic UM as discussed in the following part.

4.1. Low Mutational Burden, Few Neoantigens, and Low PD-L1 Expression

Several studies have shown that ICB seems to be most effective in tumors with a high mutational burden, such as CM, cutaneous squamous cell carcinoma, or NSCLC [132,133], as these tumors are more likely to express a broad range of neoantigens that can be recognized by CTLs [134]. The exposure to environmental noxae, such as tobacco smoke, UV radiation, and other carcinogens facilitate the accumulation of dozens of mutations and result in the formation of tumors with a high mutational burden [12]. Currently, the tumor mutational burden is the best biomarker to predict response to ICB across tumor entities. In contrast to CM, UM is a tumor with a remarkably low mutational burden of around 0.5 per Mb sequence [20]. Environmental mutagens like UV radiation have been discussed as risk factors in UM; however, their impact on UM initiation and progression seems to be quite low and is still controversial [135]. Therefore, the probability of expressing neoantigens that are recognizable for T cells is relatively low. Additionally, the fact that only about 10% of UM primary tumors [99] and 5% of the UM cells in metastatic UM sites express PD-L1 [136] may also contribute to the low susceptibility of UM to ICB mediated by anti-PD-1 or anti-PD-L1 antibodies. Nevertheless, a small subset of patients appears to benefit from ICB, and durable responses have been achieved with ICB. Rodrigues et al. report the case of a UM patient with metastases in liver, lungs, and bones who had a CR after ICB with pembrolizumab [137]. Another UM patient, who had received ipilimumab plus pembrolizumab had an SD for 10 months and a prolonged survival of 2 years in the metastatic stage [138]. The tumors of both patients were characterized by an extraordinary high mutational burden and the presence of germline mutations of methyl-CpG-binding domain protein 4 (MBD4) [137,138] that are found in about 2% of UM patients [137]. Like the frequently in UM mutated BAP1, the MBD4 gene is located on chromosome 3 (3q21.3) [139]. MBD4 mutations are also present in up to 43% of colorectal, endometrial, gastric, and pancreatic cancer with microsatellite instability [139]. The protein acts as a DNA glycosylase and is involved in the base excision repair mechanism where it initiates the removal of deaminated cytosines and 5-methylcytosines and, in particular, thymine and uracil incorrectly pairing with guanine within CpG dinucleotides [140]. Altogether, these findings indicate that the low mutational burden of UM significantly contributes to the weak ICB susceptibility.

4.2. Development of the Primary Tumor in an Immune-Privileged Organ

UM arises in the eye in an immune-privileged environment that possesses inhibitory properties against both the innate and the adaptive immune system [141]. This may protect cancer cells not only at the site of the primary tumor but also may hamper a successful anti-tumor immune response in other sites of the body and thus contribute to ICB failure in UM. In contrast, autoimmune-mediated diseases such as uveitis can severely affect the eye. Nevertheless, several mechanisms in the eye, including physical barriers, the presence of immunosuppressive cells, and soluble as well as membrane-bound immune modulators, protect the sensitive retinal tissue from excessive immune responses that may cause vision loss and blindness [141]. The special anatomical structure of the eye limits the access of immune
cells to the surrounding tissue through tight junctions between vascular endothelial cells forming the blood-ocular barrier and a lack of lymphatic vessels [142,143]. Additionally, soluble factors in the aqueous humor, including transforming growth factor-β (TGF-β), macrophage migration-inhibitory factor (MIF), vasointestinal polypeptide (VIP), and α-melanocyte-stimulating hormone (α-MSH) [144] dampen the immune response by inhibiting the IFN-γ secretion of activated CD4+ T cells [145]. TGF-β also inhibits the activity of proinflammatory macrophages [144] and upregulates CTLA-4 on CTLs, which promotes the formation of immunosuppressive Tregs [146]. Tregs are found in up to 24% of UM primary tumors, and their presence is associated with a poor prognosis [147]. Tregs formation is also stimulated by α-MSH, another soluble factor that is physiologically present in the aqueous humor [148], and can dampen neutrophil activation [142]. The soluble factor MIF is able to inhibit cell lysis mediated by natural killer (NK) cells [149]. As a part of the innate immune system, NK cells are able to recognize and destroy cells with a decreased or lacking MHC class I expression that would evade CTLs otherwise [150]. NK cells are able to destroy UM cells in vitro [151]. However, in contrast to most other tumors including CM [152], loss of MHC class I expression in UM is associated with a better prognosis [153,154].

UM cells not only evolve in an immunosuppressive environment, but they are also able to create or maintain this favorable environment also in other sites of the body by fostering mostly tumor-promoting immune cells and blocking tumor-killing T cells and NK cells. This is achieved by producing soluble mediators, such as TGF-β [155], α-MSH, and MIF [156], that are also present in the healthy eye. The expression of the membrane-bound PD-L1 was found in the retina, cornea, and iris [157–159], but also on UM cells [160]. However, unlike CM, only about 10% of UM primary tumors [99] and 5% of the UM cells in metastatic UM sites express PD-L1, but about 50% of tumor-infiltrating lymphocytes (TILs) express its receptor PD-1 [136]. Tumor-infiltrating immune cells in UM are mostly T cells and smaller numbers of NK cells, B cells, and macrophages [161]. Interestingly, a higher number of TILs has been associated with a worse prognosis in UM [162]. Macrophages in UM are mostly of the M2 phenotype, which facilitates angiogenesis and immunosuppression by producing anti-inflammatory cytokines such as TGF-β and IL-10, which dampen the activation and function of T cells, NK cells, and DCs [163]. Chemokines like CCL2 and CCL22, which are released by UM cells, promote the polarization towards this phenotype [164]. The presence of M2 macrophages in UM may also explain why a high number of TAMs in UM is also associated with a poorer prognosis [165].

4.3. Liver as an Immune-Modulating Organ

The liver is the primary organ where UM metastases develop. At time of death, hepatic metastases are present in more than 90% of UM patients [48]. Interestingly, the liver also acts as an immune-modulating organ. It is the first organ which the blood from the gastrointestinal tract passes and therefore needs a tightly balanced immune response in order to defeat pathogens like microbes and viruses quickly but maintain tolerance against harmless dietary antigens. This response is predominantly mediated via the components and resident cells of the innate immune system including the complement system and NK cells [166].

NK cells seem to play an important role in UM tumor growth and the establishment of hepatic metastases. Lymphocyte distribution in the liver significantly differs from other sites of the human body. About 30% to 50% of all lymphocytes in the liver are NK cells compared to 5% to 20% in the peripheral blood [167]. Disrupting the NK cell function in mouse models increased the number of UM liver metastases, whereas promoting NK cell function by interferon-β application resulted in a decreased formation of liver metastases [168,169]. These data indicate that UM cells are generally susceptible to NK-cell-mediated killing in the liver but may be protected in the immunosuppressive environment in the eye. Metastatic UM cells residing in the liver have developed several strategies to circumvent NK cell-mediated lysis. UM cell lines derived from hepatic metastases show a stronger production of MIF, a cytokine that inhibits NK cell function [156]. NK cells are activated via the natural-killer group 2 member D (NKG2D) receptor on their cell surface, which interacts with MHC
class I related chain (MIC)-A/B molecules [170]. MIC-A/Bs are nonclassical MHC molecules and are expressed on the cell surface of various tumor entities, including about 50% of primary UMs [171]. Interestingly, it is absent in UM liver metastases, indicating that a decreased MIC-A/B expression also contributes to immune escape from NK-cell-mediated tumor cell lysis in the liver [171]. Besides this, the adaptive immune response against hepatic metastases is rather weak. Only small numbers of CTLs are found in UM liver metastases, and these are mostly observed peritumorally [172]. Thus, the infiltration of lymphocytes into the tissue is weak, and cell lysis mediated by CTLs seems to play a minor role in this process, indicating that ICB, which aims to boost the T cell-mediated anti-tumor response, is likely to fail. Besides this low accessibility to CTLs, only about 5% of the tumor cells in metastatic UM sites and 50% of TILs express PD-1 [136]. These observations are in line with several studies that showed poorer response rates of anti-PD-1 therapy also in CM with liver metastasis, also indicating that the T cell response in this organ plays only a minor role in tumor growth control [173,174]. Additionally, in the phase II study reported by Johnson et al. [123], the only patients who responded were those without or with only small hepatic metastases, and in the study presented by Rossi et al. [126], patients with liver metastases had a much lower median PFS compared to patients with extrahepatic metastases.

4.4. Making Cold Tumors Hot for Immune Cells: Considerations for Future Immunotherapies

A special immune-modulating environment at the sites of the primary tumor, the liver as the preferred place for metastatic disease, and acquiring immunosuppressive properties help UM cells to evade from an anti-tumoral immune response. This partly explains why UM is less responsive to ICB than other cancer entities. However, despite the low number of neoantigens, UM expresses a couple of immunogenic antigens as melanoma antigen recognized by T cells (MART-1/Melan-A), glycoprotein 100 (gp100), tyrosinase, tyrosinase-related protein-1 (TRP-1) [175], or melanoma-associated antigen (MAGE) [176]. Furthermore, CTLs isolated from UM primary tumor tissue [177] or the peripheral blood of UM patients [178] as well as NK cells [151] are able to lyse UM cells in vitro. These findings demonstrate that other therapy options may be able to enhance an antitumoral immune response in UM despite the poor ICB results. Thus, is there a chance to develop an immunotherapy that can effectively mediate a successful antitumor response?

Highly expressed antigens such as MART1, gp100, or TRP-1 may be suitable targets for, e.g., dendritic cell (DC) vaccination approaches. DCs are professional APCs and are required for the induction of an antigen-specific immune reaction by presenting captured antigens via MHC class I and II molecules to naïve CD8+ and CD4+ T cells [179]. Therapeutic DC vaccination uses this mechanism to provoke a specific antitumor immune response by generating tumor-specific CD8+ T cells and efficient CD4+ T helper cells. Monocytes or other hematopoietic progenitors are isolated from the tumor patient via leukapheresis and cultured in the presence of stimulatory cytokines such as IL-4 and granulocyte-macrophage colony-stimulating factor (GM-CSF) [179,180]. These monocyte-derived DCs are then loaded with tumor-specific peptides (i.e., gp100, tyrosinase) or mRNA encoding these antigens and retransferred into the patient [180] (Figure 2). In the last years, DC vaccination showed several promising results. A phase I/II trial investigating autologous DCs loaded with gp100 and tyrosinase in 14 metastatic UM patients achieved an antitumor immune response in four patients (29%), one SD, and a median OS with metastatic disease of 19.2 months. No serious AEs of grades 3 or 4 were reported, and the most frequently reported AEs were flu-like symptoms (eight patients, 57%), erythema at the site of the DC injection (six patients, 43%), and fatigue (five patients, 36%) [180]. Another open-label, nonrandomized phase II trial (NCT00929019) investigated DC vaccination in an adjuvant setting compared to observation only. Twenty-three UM patients with a high risk for developing metastases as characterized by monosomy 3 received autologous DCs loaded with tumor mRNA after resection of the primary tumor. DC vaccination achieved a 3-year OS of 79% and a median disease-free survival of 34.5 months. Similar to the study mentioned above, no grade 3 or 4 toxicities were observed, and the most common AEs were flu-like symptoms (21 patients, 91%) and
erythema at the site of the DC injection (20 patients, 87%) [181]. Currently, a multicenter, open-label, randomized phase III trial investigating adjuvant DC vaccination versus observation only is ongoing (NCT01983748) [182]. Patients receive autologous DCs loaded with tumor mRNA intravenously over a period of 2 years or standard care with observation only and staging every three months.

Figure 2. Promising future immunotherapy options for UM patients. (A) Dendritic cell vaccination: Monocytes or other hematopoietic progenitors are isolated from the tumor patient via leukapheresis and develop in vitro in the presence of stimulatory cytokines to mature DCs. These are then loaded with tumor-specific peptides (i.e., gp100, tyrosinase) or mRNA encoding these antigens and retransferred into the patient in order to boost the anti-tumor response. (B) Adoptive T cell transfer: TILs are isolated from hepatic metastases and expanded in vitro. After a lymphodepleting chemotherapy, the patient receives the expanded TILs followed by IL-2 administration. (C) Bispecific proteins, i.e., IMCgp100 (tebentafusp): The bispecific protein IMCgp100 combines a TCR against gp100 and CD3 scFv. The engineered TCR of the molecule binds to gp100 on UM cells presented by the MHC class I protein HLA-A*02:01, and the anti-CD3 antibody fragment binds to and activates CD3+ T cells. DC = dendritic cell, TILs: tumor-infiltrating lymphocytes, CD3 scFv = anti-CD3 single-chain antibody fragment, MHC I = major histocompatibility complex I, TCR = T cell receptor, IL-2 = interleukin-2.

The adoptive transfer of tumor-infiltrating lymphocytes (TILs) involves the isolation of TILs from hepatic metastases and their expansion in vitro. Before the expanded cells are retransferred, followed by a T-cell-stimulating IL-2 administration, the patients receive a lymphodepleting chemotherapy. This therapy option has shown promising results in a phase II trial (NCT01814046). Twenty-one HLA-A2-positive UM patients with hepatic metastases were included, and 20 patients were evaluable. One patient had a CR and six patients a PR (30%). Severe AEs of grade 3 and higher, including lymphopenia, neutropenia, and thrombocytopenia, were observed in all 21 patients, and 14 patients (67%) had a grade 3 anemia. These were most likely caused by the lymphodepleting chemotherapy but not by the adoptive T cell transfer itself. [151,183]. Currently, an interventional, open-label phase II trial
(NCT03467516) investigating adoptive TIL transfer in metastatic UM patients has finished recruiting and will evaluate the ORR, CR rate, duration of response, disease control rate, PFS, and OS.

Another attempt includes IMCgp100 (tebentafusp), a bispecific protein that combines a TCR recognizing gp100 and an anti-CD3 single-chain antibody fragment (scFv). The engineered TCR binds to gp100 on UM cells presented by the MHC class I protein HLA-A*02:01 and the anti-CD3 antibody fragment binds to and activates CD3+ T cells [184]. IMCgp100 has achieved encouraging results in phase I/II trials. In a phase I first-in-human trial (NCT01211262) including 14 UM patients, two PR (14%), 8 SD (57%) and 4 PD (29%) were observed. [185]. Another phase I study (NCT02570308) investigated intra-patient escalating doses of IMCgp100 in 19 heavily pretreated metastatic UM patients. Two PR (11%) were observed in this trial, the median PFS was 5.6 months and the 1-year PFS was 62%, the 1-year OS 79.5% (95% CI 55–93), median OS was not yet reached. Rash (90%), pruritus (90%) and edema (63%) were the most frequently observed AEs. Similar to the first-in-human study, hypotension (16%) was the most frequent severe AE of grade 3 and higher [186]. Currently, a randomized controlled trial comparing IMCgp100 vs. physician’s choice chemotherapy or immunotherapy is recruiting patients with advanced UM (NCT03070392).

In highly prevalent tumor types, the use of high-throughput data (HTD) technologies for molecular profiling like DNA and RNA sequencing generates currently valuable knowledge to elucidate the molecular relationships behind pathogenesis, improve diagnostics, find druggable targets, and assess the mechanisms of resistance to therapy. The application of these technologies to UM is in its infancy [30]. However, in general, parallel and hierarchical integration analyses used for CM should also be applicable to other cancer entities as well [187]. These new techniques could significantly contribute to the understanding of UM pathogenesis and metastatic spread but also to the adaptation of therapies successful in other tumor entities like CM. As indicated, the liver is an immune-regulating organ which UM tumors benefit from developing. HTD techniques can be used to dissect the molecular features that make the liver microenvironment advantageous for UM. The use of single-cell RNA sequencing can provide detailed information about the populations of stromal and immune cells interacting in the tumor niche (see [188] for an example in CM). When combined with network biology methodologies, the RNA sequencing data can provide clues about the specific transcriptional programs that tumor and immune cells have activated [189,190]. The deep understanding of these programs, which govern key tumor and immune cell phenotypes, can help in finding molecular targets for coadjuvant therapy making UM cold tumors hot [191]. We also mentioned that UMs often have a low number of neoantigens, but still a number of overexpressed proteins holding immunogenic antigens. RNA sequencing analysis of tumor samples, differential expression, and computational algorithms for epitope detection can be combined to select in a personalized manner T cell epitopes from overly expressed proteins, which could be used in DC- or epitope-based immunotherapy [192].

5. Conclusions

UM is a rare malignancy and by far less susceptible to ICB than CM. Its genetic characteristics and the ability to adopt immunosuppressive strategies from the sites where it originates help UM cells to evade from the immune system and lead to checkpoint inhibitor resistance. However, some promising therapy approaches that aim to modulate and enhance the antitumoral immune response are in the pipeline and might prove successful in the next few years. As a subset of patients shows durable responses and clinical benefit to combined ICB, future studies are urgently warranted to better characterize and understand the underlying mechanisms of response.

Author Contributions: Conceptualization, A.W., C.B. and M.V.H.; writing—original draft preparation, A.W., T.S., M.E., J.V., L.H., M.S. and C.B.; visualization, A.W. and T.S.; supervision: M.V.H. All authors have read and agreed to the published version of the manuscript.

Funding: The authors have not received external funding for the preparation of the manuscript. Scientific studies on uveal melanoma were supported by a grant of the Helmut Legerlotz Stiftung and the Matthias Lackas Stiftung to C.B.
Conflicts of Interest: L.H. has received fees as consultant/member of advisory boards by Amgen, MSD, BMS, Roche, Curevac, Pierre-Fabre, Novartis, and Sanofi-Aventis and research grants to institution from Novartis. M.S. received honoraria for lectures from MSD, BMS, Roche, and Pierre-Fabre and served on advisory boards for Novartis, Roche, MSD, and Pierre-Fabre. C.B. has received speaker’s honoraria or fees as member of advisory boards by Amgen, BMS, Immunocore, Merck, MSD, Novartis, Pierre Fabre, Roche, and Sanofi-Aventis. C.B. has been investigator of clinical trials sponsored by Amgen, Array Pharma, AstraZeneca, BMS, MSD, Novartis, Regeneron, and Roche. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; nor in the decision to publish the results. All other authors declare no conflict of interest.

Abbreviations

α-MSH  \[\alpha\text{-melanocyte-stimulating hormone}\]
APCs  \[\text{antigen-presenting cells}\]
BAP1  \[\text{BRCA1-associated protein 1}\]
BRAF  \[\text{v-Raf murine sarcoma viral oncogene homolog}\]
CI   \[\text{confidence interval}\]
CM  \[\text{cutaneous melanoma}\]
CR  \[\text{complete response}\]
CTLA-4  \[\text{cytotoxic T lymphocyte-associated antigen 4}\]
CTLs  \[\text{cytotoxic CD8+ T lymphocytes}\]
CYSLTR2  \[\text{G-protein coupled cysteinyl leukotriene receptor 2}\]
DC  \[\text{dendritic cell}\]
DCR  \[\text{disease control rate}\]
EAP  \[\text{expanded access program}\]
EIF1AX  \[\text{eukaryotic translation initiation factor 1A, x-linked}\]
FDA  \[\text{US Food and Drug Administration}\]
GM-CSF  \[\text{granulocyte-macrophage colony-stimulating factor}\]
GNA11  \[\text{guanine nucleotide-binding protein \(\alpha11\)}\]
GNAQ  \[\text{guanine nucleotide-binding protein Q polypeptide}\]
gp100  \[\text{glycoprotein 100}\]
HGF  \[\text{hepatic growth factor}\]
HLA  \[\text{human leukocyte antigen}\]
ICB  \[\text{immune checkpoint blockade}\]
IDO  \[\text{indoleamine 2,3-dioxygenase}\]
IFN-\(\gamma\)  \[\text{interferon-\(\gamma\)}\]
IGF-1  \[\text{insulin-like growth factor-1}\]
IL  \[\text{Interleukin}\]
MAGE  \[\text{melanoma-associated antigen}\]
MAPK  \[\text{mitogen-activated protein kinase}\]
MART-1/Melan-A  \[\text{melanoma antigen recognized by T cells}\]
MBD4  \[\text{methyl-CpG-binding domain protein 4}\]
MHC  \[\text{major histocompatibility complex}\]
MIC  \[\text{MHC class I related chain}\]
MIF  \[\text{macrophage migration-inhibitory factor}\]
NK cells  \[\text{natural killer cells}\]
NKG2D  \[\text{natural-killer group 2 member D receptor}\]
NRAS  \[\text{neuroblastoma rat sarcoma viral oncogene homolog}\]
NSCLC  \[\text{non-small cell lung cancer}\]
ORR  \[\text{objective response rate}\]
OS  \[\text{overall survival}\]
PD  \[\text{progressive disease}\]
PD-1  \[\text{programmed death-1}\]
PD-L1  \[\text{programmed death ligand 1}\]
PD-L2  \[\text{programmed death ligand 2}\]
PFS progression-free survival
PI3K phosphoinositide 3-kinase
PKC protein kinase C
PLCB4 phospholipase C β4
PR partial response
PTEN phosphatase and tensin homolog
scFv single-chain antibody fragment
SD stable disease
SF3B1 splicing factor 3B, subunit 1
TAC transarterial chemotherapy
TACE transarterial chemoembolization
TAMs tumor-associated macrophages
TCR T cell receptor
TGF-β transforming growth factor-β
TILs tumor-infiltrating lymphocytes
TNF-α tumor necrosis factor-α
Tregs regulatory T cells
TRP-1 tyrosinase-related protein-1
UM uveal melanoma
UV Ultraviolet
VCAM-1 vascular cell adhesion molecule-1
VIP vasointestinal polypeptide

References

1. McLaughlin, C.C.; Wu, X.C.; Jemal, A.; Martin, H.J.; Roche, L.M.; Chen, V.W. Incidence of noncutaneous melanomas in the U.S. Cancer 2005, 103, 1000–1007. [CrossRef] [PubMed]
2. Chang, A.E.; Karnell, L.H.; Menck, H.R. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: A summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998, 83, 1664–1678. [CrossRef]
3. Chattopadhyay, C.; Kim, D.W.; Gombos, D.S.; Oba, J.; Qin, Y.; Williams, M.D.; Esmaeli, B.; Grimm, E.A.; Wargo, J.A.; Woodman, S.E.; et al. Uveal melanoma: From diagnosis to treatment and the science in between. Cancer 2016, 122, 2299–2312. [CrossRef] [PubMed]
4. Mallone, S.; De Vries, E.; Guzzo, M.; Midena, E.; Verne, J.; Coebergh, J.W.; Marcos-Gragera, R.; Ardanaz, E.; Martinez, R.; Chirlaque, M.D.; et al. Descriptive epidemiology of malignant mucosal and uveal melanomas and adnexal skin carcinomas in Europe. Eur. J. Cancer 2012, 48, 1167–1175. [CrossRef] [PubMed]
5. Weis, E.; Shah, C.P.; Lajous, M.; Shields, J.A.; Shields, C.L. The association of cutaneous and iris nevi with uveal melanoma: A meta-analysis. Ophthalmology 2009, 116, 536–543.e2. [CrossRef] [PubMed]
6. Weis, E.; Shah, C.P.; Lajous, M.; Shields, J.A.; Shields, C.L. The association between host susceptibility factors and uveal melanoma: A meta-analysis. Arch. Ophthalmol. 2006, 124, 54–60. [CrossRef]
7. Shields, C.L.; Kaliki, S.; Livesey, M.; Walker, B.; Garoon, R.; Bucci, M.; Feinstein, E.; Pesch, A.; Gonzalez, C.; Lally, S.E.; et al. Association of ocular and ocudermal melanocytosis with the rate of uveal melanoma metastasis: Analysis of 7872 consecutive eyes. JAMA Ophthalmol. 2013, 131, 993–1003. [CrossRef]
8. Singh, A.D.; De Potter, P.; Fijal, B.A.; Shields, C.L.; Shields, J.A.; Elston, R.C. Lifetime prevalence of uveal melanoma in white patients with oculodermal melanocytosis. Ophthalmology 1998, 105, 195–198. [CrossRef]
9. Gupta, M.P.; Lane, A.M.; DeAngelis, M.M.; Mayne, K.; Crabtree, M.; Gragoudas, E.S.; Kim, I.K. Clinical Characteristics of Uveal Melanoma in Patients With Germline BAP1 Mutations. JAMA Ophthalmol. 2015, 133, 881–887. [CrossRef]
10. Murali, R.; Wiesner, T.; Scolyer, R.A. Tumours associated with BAP1 mutations. Pathology 2013, 45, 116–126. [CrossRef]
11. Shah, C.P.; Weis, E.; Lajous, M.; Shields, J.A.; Shields, C.L. Intermittent and chronic ultraviolet light exposure and uveal melanoma: A meta-analysis. Ophthalmology 2005, 112, 1599–1607. [CrossRef] [PubMed]
32. Harbour, J.W.; Onken, M.D.; Roberson, E.D.; Duan, S.; Cao, L.; Worley, L.A.; Council, M.L.; Matatall, K.A.; Helms, C.; Bowcock, A.M. Frequent mutation of BAP1 in metastasizing primary uveal melanomas. Science 2010, 330, 1410–1413. [CrossRef] [PubMed]

33. Ismail, I.H.; Davidson, R.; Gagne, J.P.; Xu, Z.Z.; Poirier, G.G.; Hendzel, M.J. Germline mutations in BAP1 impair its function in DNA double-strand break repair. Cancer Res. 2014, 74, 4282–4294. [CrossRef] [PubMed]

34. Njauw, C.N.; Kim, I.; Piris, A.; Gabree, M.; Taylor, M.; Lane, A.M.; DeAngelis, M.M.; Gragoudas, E.; Duncan, L.M.; Tsao, H. Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PLoS One 2012, 7, e35295. [CrossRef]

35. Ali, M.U.; Ur Rahman, M.S.; Jia, Z.; Jiang, C. Eukaryotic translation initiation factors and cancer. Tumour Biol 2017, 39, 1010428317709805. [CrossRef]

36. Alsafadi, S.; Houy, A.; Battistella, A.; Popova, T.; Wassef, M.; Henry, E.; Tirole, F.; Constantinou, A.; Piperno-Neumann, S.; Roman-Roman, S.; et al. Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage. Nat. Commun. 2016, 7, 10615. [CrossRef]

37. Martin, M.; Masshofer, L.; Temming, P.; Rahmann, S.; Van de Nes, J.; Klein-Hitpass, L.; Horsman, D.E.; Sroka, H.; Rootman, J.; White, V.A. Monosomy 3 and isochromosome 8q in a uveal melanoma. Cancer Genet. Cytogenet. 1990, 45, 249–253. [CrossRef]

38. Horsman, D.E.; Sroka, H.; Rootman, J.; White, V.A. Monosomy 3 and isochromosome 8q in a uveal melanoma. Cancer Genet. Cytogenet. 1990, 45, 249–253. [CrossRef]

39. Prescher, G.; Bornfeld, N.; Becher, R. Nonrandom chromosomal abnormalities in primary uveal melanoma. J. Natl. Cancer. Inst. 1990, 82, 1765–1769. [CrossRef]

40. Tschentscher, F.; Prescher, G.; Zeschning, M.; Horsthemke, B.; Lohmann, D.R. Identification of chromosomes 3, 6, and 8 aberrations in uveal melanoma by microsatellite analysis in comparison to comparative genomic hybridization. Cancer Genet. Cytogenet. 2000, 122, 13–17. [CrossRef]

41. Aalto, Y.; Eriksson, L.; Seregard, S.; Larsson, O.; Knuutila, S. Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, 8 in metastasizing primary uveal melanoma. Invest. Ophthal. Vis. Sci. 2001, 42, 313–317.

42. Coupland, S.E.; Lake, S.L.; Zeschning, M.; Damato, B.E. Molecular pathology of uveal melanoma. Eye (Lond.) 2013, 27, 230–242. [CrossRef] [PubMed]

43. Seibel, I.; Cordini, D.; Rehak, M.; Hager, A.; Riechardt, A.I.; Boker, A.; Heufelder, J.; Weber, A.; Gollrad, J.; Besserer, A.; et al. Local Recurrence After Primary Proton Beam Therapy in Uveal Melanoma: Risk Factors, Retreatment Approaches, and Outcome. Am. J. Ophthalmol. 2015, 160, 628–636. [CrossRef] [PubMed]

44. Weis, E.; Salopek, T.G.; McKinnon, J.G.; Larocque, M.P.; Temple-Oberle, C.; Cheng, T.; McWhae, J.; Sloboda, R.; Shea-Budgell, M. Management of uveal melanoma: A consensus-based provincial clinical practice guideline. Curr. Oncol. 2016, 23, e57–e64. [CrossRef] [PubMed]

45. Nathan, P.; Cohen, V.; Coupland, S.; Curtis, K.; Damato, B.; Evans, J.; Fenwick, S.; Kirkpatrick, L.; Li, O.; Marshall, E.; et al. Uveal Melanoma UK National Guidelines. Eur. J. Cancer 2015, 51, 2404–2412. [CrossRef]

46. Krantz, B.A.; Dave, N.; Komatsubara, K.M.; Marr, B.P.; Carvajal, R.D. Uveal melanoma: Epidemiology, etiology, and treatment of primary disease. Clin. Ophthal. 2017, 11, 279–289. [CrossRef]

47. Kuivala, E.; Makitie, T.; Kivela, T. Very long-term prognosis of patients with malignant uveal melanoma. Invest. Ophthal. Vis. Sci. 2003, 44, 4651–4659. [CrossRef]

48. Collaborative Ocular Melanoma Study. G. Assessment of metastastic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch. Ophthal. 2001, 119, 670–676. [CrossRef]

49. van den Bosch, T.; Koopmans, A.E.; Vaarwater, J.; van den Berg, M.; de Klein, A.; Verdiijk, R.M. Chemokine receptor CCR7 expression predicts poor outcome in uveal melanoma and relates to liver metastasis whereas expression of CXCR4 is not of clinical relevance. Invest. Ophthal. Vis. Sci. 2013, 54, 7354–7361. [CrossRef] [PubMed]
52. Bakalian, S.; Marshall, J.C.; Logan, P.; Faingold, D.; Maloney, S.; Di Cesare, S.; Martins, C.; Fernandes, B.F.; Burnier, M.N., Jr. Molecular pathways mediating liver metastasis in patients with uveal melanoma. *Clin. Cancer Res.* **2008**, *14*, 951–956. [CrossRef] [PubMed]

53. Franklin, C.; Livingstone, E.; Roesh, A.; Schilling, B.; Schadendorf, D. Immunotherapy in melanoma: Recent advances and future directions. *Eur. J. Surg. Oncol.* **2017**, *43*, 604–611. [CrossRef] [PubMed]

54. Marquez-Rodas, I; Cerezuela, P; Soria, A; Berrocal, A; Riso, A; Gonzalez-Cao, M; Martin-Algarra, S. Immune checkpoint inhibitors: Therapeutic advances in melanoma. *Ann. Transl. Med.* **2015**, *3*, 267. [CrossRef] [PubMed]

55. Singh, A.D.; Turell, M.E.; Topham, A.K. Uveal melanoma: Trends in incidence, treatment, and survival. *Ophthalmology* **2011**, *118*, 1881–1885. [CrossRef]

56. Kuk, D.; Shoushtari, A.N.; Barker, C.A.; Panageas, K.S.; Munhoz, R.R.; Mottaz, P.; Arian, C.E.; Brady, M.S.; Coit, D.G.; Bogatch, K.; et al. Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis. *Oncologist* **2016**, *21*, 848–854. [CrossRef]

57. Onken, M.D.; Worley, L.A.; Ehlers, J.P.; Harbour, J.W. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. *Cancer Res.* **2004**, *64*, 7205–7209. [CrossRef]

58. Prescher, G.; Bornfeld, N.; Hirche, H.; Horsthemke, B.; Jockel, K.H.; Becher, R. Prognostic implications of monosomy 3 in uveal melanoma. *Lancet* **1996**, *347*, 1222–1225. [CrossRef]

59. Damato, B.; Dopiera, J.A.; Coupland, S.E. Genotypic profiling of 452 choroidal melanomas with multiplex ligation-dependent probe amplification. *Clin. Cancer Res.* **2010**, *16*, 6083–6092. [CrossRef]

60. Jensen, D.E.; Proctor, M.; Marquis, S.T.; Gardner, H.P.; Ha, S.J.; Chodosh, L.A.; Ishov, A.M.; Tommerup, N.; Vissing, H.; Sekido, Y.; et al. BAP1: A novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. *Oncogene* **1998**, *16*, 1097–1112. [CrossRef]

61. White, V.A.; Chambers, J.D.; Courtright, P.D.; Chang, W.Y.; Horsman, D.E. Correlation of cytogenetic abnormalities with the outcome of patients with uveal melanoma. *Cancer* **1998**, *83*, 354–359. [CrossRef]

62. Staby, K.M.; Gravdal, K.; Mork, S.J.; Heegaard, S.; Vintermyr, O.K.; Krohn, J. Prognostic impact of chromosomal abnormalities and GNAQ, GNA11, BAP1, SF3B1, EIF1AX and TERT mutations in uveal melanoma. *Acta Ophthalmol* **2018**, *96*, 31–38. [CrossRef]

63. Dono, M.; Angelini, G.; Cecconi, M.; Amaro, A.; Esposito, A.I.; Mirisola, V.; Maric, I.; Lanza, F.; Nacciuti, F.; Viaggi, S.; et al. Mutation frequencies of GNAQ, GNA11, BAP1, SF3B1, EIF1AX and TERT in uveal melanoma: Detection of an activating mutation in the TERT gene promoter in a single case of uveal melanoma. *Br. J. Cancer* **2014**, *110*, 1058–1065. [CrossRef]

64. Yavuzyigitoglu, S.; Koopmans, A.E.; Verdijk, R.M.; Vaarwater, J.; Eussen, B.; van Bodegom, A.; Paridaens, D.; Kilic, E.; de Klein, A.; Rotterdam Ocular Melanoma Study, G. Uveal Melanomas with SF3B1 Mutations: A Distinct Subclass Associated with Late-Onset Metastases. *Ophthalmology* **2016**, *123*, 1118–1128. [CrossRef]

65. Agarwala, S.S.; Koopmans, A.E.; Verdijk, R.M.; Vaarwater, J.; Eussen, B.; van Bodegom, A.; Paridaens, D.; Kilic, E.; de Klein, A.; Rotterdam Ocular Melanoma Study, G. Uveal Melanomas with SF3B1 Mutations: A Distinct Subclass Associated with Late-Onset Metastases. *Ophthalmology* **2016**, *123*, 1118–1128. [CrossRef]

66. Schuster, R.; Lindner, M.; Wacker, F.; Krossin, M.; Bechrakis, N.; Foerster, M.H.; Thiel, E.; Keilholz, U.; Schmittel, A. Transarterial chemoembolization of liver metastases from uveal melanoma after failure of systemic therapy: Toxicity and outcome. *Melanoma Res.* **2010**, *20*, 191–196. [CrossRef]

67. Wright, C.J.; McCormack, P.L. Trametinib: First global approval. *Drugs* **2013**, *73*, 1245–1254. [CrossRef]

68. Garnock-Jones, K.P. Cobimetinib: First Global Approval. *Drugs* **2015**, *75*, 1823–1830. [CrossRef]

69. Shirley, M. Encorafenib and Binimetinib: First Global Approvals. *Drugs* **2018**, *78*, 1277–1284. [CrossRef]

70. Steeb, T.; Wessely, A.; Ruzicka, T.; Heppt, M.V.; Berking, C. How to MEK the best of uveal melanoma: A systematic review on the efficacy and safety of MEK inhibitors in metastatic or unresectable uveal melanoma. *Eur. J. Cancer* **2018**, *103*, 41–51. [CrossRef]

71. A Phase Ib/II, Open-label, Multicenter Study of AE3071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma (NCT01801358). Available online: https://clinicaltrials.gov/ct2/show/NCT01801358 (accessed on 3 December 2019).

72. Carvajal, R.D.; Carvajal, R.D.; Piperno-Neumann, S.; Kapiteijn, E.; Chapman, P.B.; Frank, S.; Joshua, A.M.; Piulats, J.M.; Wolter, P.; Cocquyt, V.; Chmielowski, B.; et al. Selumetinib in Combination With Dacarbazine in Patients
94. Freeman, G.J.; Long, A.J.; Iwai, Y.; Bourque, K.; Chernova, T.; Nishimura, H.; Fitz, L.J.; Malenkovich, N.; Okazaki, T.; Byrne, M.C.; et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 2000, 192, 1027–1034. [CrossRef] [PubMed]

95. Parry, R.V.; Chemnitz, J.M.; Frauwirth, K.A.; Lanfranco, A.R.; Braunstein, I.; Kobayashi, S.V.; Linsley, P.S.; Thompson, C.B.; Riley, J.L. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell Biol. 2005, 25, 9543–9553. [CrossRef]

96. Buchbinder, E.I.; Desai, A. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am. J. Clin. Oncol. 2016, 39, 98–106. [CrossRef]

97. Ohaegbulam, K.C.; Assal, A.; Lazar-Molnar, E.; Yao, Y.; Zang, X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol. Med. 2015, 21, 24–33. [CrossRef]

98. Dong, Y.; Sun, Q.; Zhang, X. PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget 2017, 8, 2171–2186. [CrossRef]

99. Kaunitz, G.J.; Cottrell, T.R.; Lilo, M.; Muthappan, V.; Esandrio, J.; Berry, S.; Xu, H.; Ogurtsova, A.; Anders, R.A.; Fischer, A.H.; et al. Melanoma subtypes demonstrate distinct PD-L1 expression profiles. Lab. Invest. 2017, 97, 1063–1071. [CrossRef]

100. Herbst, R.S.; Baas, P.; Kim, D.W.; Felip, E.; Perez-Gracia, J.L.; Han, J.Y.; Molina, J.; Kim, J.H.; Arvis, C.D.; Ahn, M.J.; et al. Pembrolizumab versus docetaxel for previously treated, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet 2016, 387, 1540–1550. [CrossRef]

101. Hamanishi, J.; Mandai, M.; Iwasaki, M.; Okazaki, T.; Tanaka, Y.; Yamaguchi, K.; Higuchi, T.; Yagi, H.; Takakura, K.; Minato, N.; et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 3360–3365. [CrossRef]

102. Cimino-Mathews, A.; Thompson, E.; Taube, J.M.; Ye, X.; Lu, Y.; Meeker, A.; Xu, H.; Sharma, R.; Lecksell, K.; Cornish, T.C.; et al. PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. Hum. Pathol. 2016, 47, 52–63. [CrossRef] [PubMed]

103. Yearley, J.H.; Gibson, C.; Yu, N.; Moon, C.; Murphy, E.; Juco, J.; Lunceford, J.; Cheng, J.; Chow, L.Q.M.; Seiwert, T.Y.; et al. PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer. Clin. Cancer Res. 2017, 23, 3158–3167. [CrossRef] [PubMed]

104. Rozeman, E.A.; Prevoo, W.; Meier, M.A.J.; Sikorska, K.; Van, T.M.; van de Wiel, B.A.; van der Wal, J.E.; Mallo, H.A.; Griepink-Ongering, L.G.; Broeks, A.; et al. Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM). Melanoma Res. 2019. [CrossRef]

105. Shaw, H.; Larkin, J.; Corrie, P.; Ellis, S.; Nobes, J.; Marshall, E.; Kumar, S.; Danson, S.; Plummer, R.; Nathan, P. Ipilimumab for Advanced Melanoma in an Expanded Access Programme (Eap): Ocular, Mucosal and Acral Subtype UK Experience. Ann. Oncol. 2012, 23, 374. [CrossRef]

106. Kelderman, S.; van der Kooij, M.K.; van den Eertwegh, A.J.; Soetekouw, P.; Jansen, R.L.; van den Brom, R.R.; Hoppers, G.A.; Haanen, J.B.; Kapiteijn, E.; Blank, C.U. Ipilimumab in pretreated metastatic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O). Acta Oncol. 2013, 52, 1786–1788. [CrossRef] [PubMed]

107. Maio, M.; Danieli, R.; Chiarion-Sileni, V.; Pigozzo, J.; Parmiani, G.; Ridolfi, R.; De Rosa, F.; Del Vecchio, M.; Di Guardo, L.; Queirolo, P.; et al. Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. Ann. Oncol. 2013, 24, 2911–2915. [CrossRef]

108. Zimmer, L.; Vaubel, J.; Mohr, P.; Hauschild, A.; Utikal, J.; Simon, J.; Garbe, C.; Herbst, R.; Enk, A.; Kampgen, E.; et al. Phase II DeCOG study of ipilimumab in pretreated and treatment-naive patients with metastatic uveal melanoma. PLoS One 2015, 10, e0118564. [CrossRef]

109. Jung, M.; Lee, J.; Kim, T.M.; Lee, D.H.; Kang, J.H.; Oh, S.Y.; Lee, S.J.; Shin, S.J. Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort. Cancer Res. Treat. 2017, 49, 44–53. [CrossRef]

110. Piulats, J.M.; Ochoa-De-Olza, M.; Lopez-Martin, J.A.; Codes, M.; Berrocal, A.; Martin-Algarra, S. Phase II study evaluating Ipilimumab monotherapy in the first-line treatment of adult patients with metastatic uveal melanoma (MUM): The GEMI trial. J. Clin. Oncol. 2014, 27, 1219.

111. Danielli, R.; Ridolfi, R.; Chiarion-Sileni, V.; Queirolo, P.; Testori, A.; Plummer, R.; Boitano, M.; Calabro, L.; Rossi, C.D.; Giacomo, A.M.; et al. Ipilimumab in pretreated patients with metastatic uveal melanoma: Safety and clinical efficacy. Cancer Immunol. Immunother. 2012, 61, 41–48. [CrossRef]
112. Fountain, E.; Bassett, R.L.; Cain, S.; Posada, L.; Gombos, D.S.; Hwv, P.; Bedikian, A.; Patel, S.P. Adjuvant Ipilimumab in High-Risk Uveal Melanoma. Cancers 2019, 11. [CrossRef] [PubMed]

113. Luke, J.J.; Callahan, M.K.; Postow, M.A.; Romano, E.; Ramaiya, N.; Bluth, M.; Giobbie-Hurder, A.; Lawrence, D.P.; Ibrahim, N.; Ott, P.A.; et al. Clinical activity of ipilimumab for metastatic uveal melanoma: A retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer 2013, 119, 3687–3695. [CrossRef] [PubMed]

114. Itchins, M.; Asciento, P.A.; Menzies, A.M.; Oatley, M.; Lo, S.; Douraghi-Zadeh, D.; Harrington, T.; Maher, R.; Grimaldi, A.M.; Guminiski, A. A multireferral centre retrospective analysis of the experience in treatment of metastatic uveal melanoma and utilization of sequential liver-directed treatment and immunotherapy. Melanoma Res. 2017, 27, 243–250. [CrossRef] [PubMed]

115. Bol, K.F.; Ellebaek, E.; Bagger, M.M.; Larsen, M.S.; Klausen, T.W.; Kohler, U.H.; Schmidt, H.; Bastholt, L.; Kiilgaard, J.F.; et al. Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma. Cancers 2019, 11. [CrossRef]

116. Joshua, A.M.; Monzon, J.G.; Mihalciou, C.; Hogg, D.; Smylie, M.; Cheng, T. A phase 2 study of tremelimumab in patients with advanced uveal melanoma. Melanoma Res. 2015, 25, 342–347. [CrossRef]

117. Schadendorf, D.; Asciento, P.A.; Haanen, J.B.A.G.; Espinosa, E.; Demidov, L.V.; Garbe, C.; Lorigan, P.; Gosas, H.; Hoeller, C.; Guren, T.K.; et al. Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172). J. Clin. Oncol. 2017, 35. [CrossRef]

118. van der Kooij, M.K.; Joosse, A.; Speetjens, F.M.; Hospers, G.A.; Bisschop, C.; de Groot, J.W.; Koornstra, R.; Tian, L.; Ding, F.; Sander, C.; Rose, A.; Pruckner, C.; Wilson, M.; Tahara, A.A.; Davar, D.D.; Kirkwood, J.M. Response to Anti-PD-1 in Metastatic Uveal Melanoma. J. Clin. Oncol. 2019, 26, 101–103. [CrossRef]

119. Namikawa, K.; Takahashi, A.; Mori, T.; Tsutsumida, A.; Suzuki, S.; Motoi, N.; Jinnai, S.; Mino, Y.; Mizuta, H.; Muto, Y.; et al. Nivolumab for patients with metastatic uveal melanoma previously untreated with ipilimumab: A single-institution retrospective study. Melanoma Res. 2020, 30, 76–84. [CrossRef]

120. Kottschade, L.A.; McWilliams, R.R.; Markovic, S.N.; Block, M.S.; Bisneto, J.V.; Pham, A.Q.; Esplin, B.L.; Dronca, R.S. The use of pembrolizumab for the treatment of metastatic uveal melanoma. Melanoma Res. 2016, 26, 300–303. [CrossRef]

121. Karydis, I.; Chan, P.Y.; Wheat, M.; Arriola, E.; Szlosarek, P.W.; Ottensmeier, C.H. Clinical activity and safety of Pembrolizumab in Ipilimumab-pre-treated patients with uveal melanoma. Oncoimmunology 2016, 5, e1143997. [CrossRef]

122. Johnson, D.B.; Bao, R.; Ancell, K.K.; Daniels, A.B.; Wallace, D.; Sosman, J.A.; Luke, J.J. Response to Anti-PD-1 in Uveal Melanoma Without High-Volume Liver Metastasis. J. Natl. Compr. Canc. Netw. 2019, 17, 114–117. [CrossRef]

123. Algazi, A.P.; Tsai, K.K.; Shoushtari, A.N.; Munhoz, R.R.; Eroglu, Z.; Piulats, J.M.; Ott, P.A.; Johnson, D.B.; Hawang, J.; Daud, A.I.; et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer 2016, 122, 3344–3353. [CrossRef]

124. Piperno-Neumann, S.; Servois, V.; Mariani, P.; Cassoux, N.; Barnhill, R.; Rodrigues, J.M. Activity of anti-PD-I drugs in uveal melanoma patients. J. Clin. Oncol. 2016, 34 (Suppl. 15), 9588. [CrossRef]

125. Rossi, E.; Pagliara, M.M.; Orteschi, D.; Dosa, T.; Sammarco, M.G.; Caputo, C.G.; Petrone, G.; Rindi, G.; Zollino, M.; Blasi, M.A.; et al. Pembrolizumab as first-line treatment for metastatic uveal melanoma. Cancer Immunol. Immunother. 2019, 68, 1179–1185. [CrossRef]

126. Shoushtari, A.N.; Navid-Azarbaijani, P.; Friedman, C.F.; Panageas, K.; Postow, M.A.; Callahan, M.K.; Mottaz, P.; Campbell, S.C.; Shames, Y.; Prempeh-Keteku, N.A.; et al. Efficacy of nivolumab and ipilimumab (Nivo plus Ipi) combination in melanoma patients (pts) treated at a single institution on an expanded-access program (EAP). J. Clin. Oncol. 2016, 34. [CrossRef]
150. Ljunggren, H.G.; Karre, K. In search of the ‘missing self’: MHC molecules and NK cell recognition. *Immunol. Today* 1990, 11, 237–244. [CrossRef]

151. Ma, D.; Niederkorn, J.Y. Transforming growth factor-beta down-regulates major histocompatibility complex class I antigen expression and increases the susceptibility of uveal melanoma cells to natural killer cell-mediated cytolysis. *Immunology* 1995, 86, 263–269.

152. Brocker, E.B.; Suter, L.; Bruggen, J.; Ruiter, D.J.; Macher, E.; Sorg, C. Phenotypic dynamics of tumor progression in human malignant melanoma. *Int. J. Cancer* 1985, 36, 29–35. [CrossRef] [PubMed]

153. Dithmar, S.; Crowder, J.; Jager, M.J.; Vigniswaran, N.; Grossniklaus, H.E. HLA class I antigen expression correlates with histological cell type in uveal melanoma. *OphthalmoLOGE* 2002, 99, 625–628. [CrossRef] [PubMed]

154. Bronkhorst, I.H.; Vu, T.H.; Jordanova, E.S.; Luyten, G.P.; Burg, S.H.; Jager, M.J. Di
tumor-infiltrating lymphocytes correlate with macrophage influx and monosomy 3 in uveal melanoma. *Investig. OphthalmoLOGE Vis. Sci.* 1997, 38, 1865–1872. [PubMed]

155. Esser, P.; Grisanti, S.; Bartz-Schmidt, K. TGF-beta in uveal melanoma. *MicroRes. Tech.* 2001, 52, 396–400. [CrossRef]

156. Repp, A.C.; Mayhew, E.S.; Apte, S.; Niederkorn, J.Y. Human uveal melanoma cells produce macrophage migration-inhibitory factor to prevent lysis by NK cells. *J. Immunol.* 2000, 165, 710–715. [CrossRef]

157. Hattori, T.; Kezuka, T.; Usui, Y.; Okunuki, Y.; Takeuchi, M.; Maruyama, K.; Haneda, M.; Shirato, S.; Goto, H. Human iris pigment epithelial cells suppress T-cell activation via direct cell contact. *Exp. Eye Res.* 2009, 89, 358–364. [CrossRef]

158. Sham, C.W.; Chan, A.M.; Kwong, J.M.; Caprioli, J.; Nusinowitz, S.; Chen, B.; Lee, J.G.; Gandhi, N.M.; Francisco, L.M.; Sharpe, A.H.; et al. Neuronal programmed cell death-1 ligand expression regulates retinal ganglion cell number in neonatal and adult mice. *J. NeurorophthalmoLOGE* 2012, 32, 227–237. [CrossRef]

159. Yang, W.; Chen, P.W.; Li, H.; Alizadeh, H.; Niederkorn, J.Y. PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro. *Investig. OphthalmoLOGE Vis. Sci.* 2008, 49, 2518–2525. [CrossRef]

160. Meecham, W.J.; Char, D.H.; Kaleta-Michaels, S. Infiltrating lymphocytes and antigen expression in uveal melanoma. *OphthalmoRes.* 1992, 24, 20–26. [CrossRef]

161. Whelchel, J.C.; Farah, S.E.; McLean, I.W.; Burnier, M.N. Immunohistochemistry of infiltrating lymphocytes in uveal malignant melanoma. *Investig. OphthalmoLOGE Vis. Sci.* 1993, 34, 2603–2606. [PubMed]

162. Bronkhorst, I.H.; Jager, M.J. Uveal melanoma: The inflammatory microenvironment. *J. Innate Immun.* 2012, 4, 454–462. [CrossRef] [PubMed]

163. Bronkhorst, I.H.; Vu, T.H.; Jordanова, E.S.; Luyten, G.P.; Burg, S.H.; Jager, M.J. Different subsets of tumor-infiltrating lymphocytes correlate with macrophage influx and monosomy 3 in uveal melanoma. *Investig. OphthalmoLOGE Vis. Sci.* 2012, 53, 5370–5378. [CrossRef] [PubMed]

164. Toivonen, P.; Makitie, T.; Kujala, E.; Kivela, T. Microcirculation and tumor-infiltrating macrophages in choroidal and ciliary body melanoma and corresponding metastases. *Investig. OphthalmoLOGE Vis. Sci.* 2004, 45, 1–6. [CrossRef] [PubMed]

165. Gao, B.; Jeong, W.I.; Tian, Z. Liver: An organ with predominant innate immunity. *Hepatology* 2008, 47, 729–736. [CrossRef] [PubMed]

166. Nemeth, E.; Baird, A.W.; O’Farrelly, C. Microanatomy of the liver immune system. *Semin. Immunopathol.* 2009, 31, 333–343. [CrossRef]

167. DithMAR, S.A.; Rusciano, D.A.; Armstrong, C.A.; Lynn, M.J.; Grossniklaus, H.E. Depletion of NK cell activity results in growth of hepatic micrometastases in a murine ocular melanoma model. *Curr. Eye Res.* 1999, 19, 426–431. [CrossRef]

168. Alizadeh, H.; Howard, K.; Mellon, J.; Mayhew, E.; Rusciano, D.; Niederkorn, J.Y. Reduction of liver metastasis of intraocular melanoma by interferon-beta gene transfer. *Investig. OphthalmoLOGE Vis. Sci.* 2003, 44, 3042–3051. [CrossRef]
171. Vetter, C.S.; Lieb, W.; Brocker, E.B.; Becker, J.C. Loss of nonclassical MHC molecules MIC-A/B expression during progression of uveal melanoma. *Br. J. Cancer* 2004, 91, 1495–1499. [CrossRef]

172. Krishna, Y.; McCarthy, C.; Kalirai, H.; Coupland, S.E. Inflammatory cell infiltrates in advanced metastatic uveal melanoma. *Hum. Pathol.* 2017, 66, 159–166. [CrossRef] [PubMed]

173. Tumeh, P.C.; Hellmann, M.D.; Hamid, O.; Tsai, K.K.; Loo, K.L.; Gubens, M.A.; Rosenblum, M.; Harview, C.L.; Taube, J.M.; Handley, N.; et al. Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. *Cancer Immunol. Res.* 2017, 5, 417–424. [CrossRef] [PubMed]

174. Buder-Bakhaya, K.; Hassel, J.C. Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment—A Review From the Melanoma Perspective and Beyond. *Front. Immunol.* 2018, 9, 1474. [CrossRef] [PubMed]

175. De Vries, T.J.; Trancikova, D.; Ruiter, D.J.; van Muijen, G.N. High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma. *Br. J. Cancer* 1998, 78, 1156–1161. [CrossRef] [PubMed]

176. Luyten, G.P.; van der Spek, C.W.; Brand, I.; Sintnicolaas, K.; de Waard-Siebinga, I.; Jager, M.J.; de Jong, P.T.; Schrier, P.I.; Luider, T.M. Expression of MAGE, gp100 and tyrosinase genes in uveal melanoma cell lines. *Melanoma Res.* 1998, 8, 11–16. [CrossRef] [PubMed]

177. Ksander, B.R.; Geer, D.C.; Chen, P.W.; Salgaller, M.L.; Rubsamen, P.; Murray, T.G. Uveal melanomas contain antigenically specific and non-specific infiltrating lymphocytes. *Curr. Eye Res.* 1998, 17, 165–173. [CrossRef] [PubMed]

178. Kan-Mitchell, J.; Liggett, P.E.; Harel, W.; Steinman, L.; Nitta, T.; Oksenberg, J.R.; Posner, M.R.; Mitchell, M.S. Lymphocytes cytotoxic to uveal and skin melanoma cells from peripheral blood of ocular melanoma patients. *Cancer Immunol. Immunother.* 1991, 33, 333–340. [CrossRef]

179. Palucka, K.; Banchereau, J. Cancer immunotherapy via dendritic cells. *Nat. Rev. Cancer* 2012, 12, 265–277. [CrossRef]

180. Bol, K.F.; Mensink, H.W.; Aarntrten, E.H.; Schreibelt, G.; Keulen, J.E.; Coulie, P.G.; de Klein, A.; Punt, C.J.; Paridaens, D.; Figdor, C.G.; et al. Long overall survival after dendritic cell vaccination in metastatic uveal melanoma patients. *Am. J. Ophthalmol.* 2014, 158, 939–947. [CrossRef]

181. Bol, K.F.; van den Bosch, T.; Schreibelt, G.; Mensink, H.W.; Keulen, J.E.; Kilic, E.; Japing, W.J.; Geul, K.W.; Westdorp, H.; Boudewijns, S.; et al. Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma. *J. Clin. Oncol.* 2015, 33, 2265–2267. [CrossRef]

182. Schuler-Thurner, B.; Bartz-Schmidt, K.U.; Bornfeld, N.; Cursiefen, C.; Fuisting, B.; Grisanti, S.; Heindl, L.M.; Holbach, L.; Keseru, M.; Knorr, H.; et al. Immunotherapy of uveal melanoma: Vaccination against cancer. *Ophthalmologe* 2016, 13, 879–887. [CrossRef] [PubMed]

183. Middleton, M.R.; Steven, N.M.; Evans, T.J.; Infante, J.R.; Sznol, M.; Mulatero, C.; Hamid, O.; Shoushtari, A.N.; Shingler, W.; Johnson, A.; et al. Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific t cell redirector with solid tumour activity: Results from the FIH study in melanoma. *J. Clin. Oncol.* 2016, 34, 3016. [CrossRef]

184. Carvajal, R.D.; Sacco, J.; Nathan, P.; Orloff, M.; Little, N.; McAlpine, C.; Krieger, D.; Hassan, N.; Hulstine, A.M.; Coughlin, C.; et al. Safety, efficacy and biology of the gp100 TCR-based bispecific T cell redirector IMCgp100 in advanced uveal melanoma. *J. Stem Cell Res. Ther.* 2018, 59, 3622. [CrossRef]

185. Wu, C.; Zhou, F.; Ren, J.; Li, X.; Jiang, Y.; Ma, S. A Selective Review of Multi-Level Omics Data Integration Using Variable Selection. *High. Throughput* 2019, 8. [CrossRef]

186. Tirosh, I.; Izar, B.; Prakadan, S.M.; Wadsworth, M.H.; Treacy, D.; Trombetta, J.J.; Rotem, A.; Rodman, C.; Lian, C.; Murphy, G.; et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. *Science* 2016, 352, 189–196. [CrossRef]
189. Jerby-Arnon, L.; Shah, P.; Cuoco, M.S.; Rodman, C.; Su, M.J.; Melms, J.C.; Leeson, R.; Kanodia, A.; Mei, S.; Lin, J.R.; et al. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. *Cell* 2018, 175, 984–997 e924. [CrossRef]

190. Dreyer, F.S.; Cantone, M.; Eberhardt, M.; Jaitly, T.; Walter, L.; Wittmann, J.; Gupta, S.K.; Khan, F.M.; Wolkenhauer, O.; Putzer, B.M.; et al. A web platform for the network analysis of high-throughput data in melanoma and its use to investigate mechanisms of resistance to anti-PD1 immunotherapy. *Biochim. Biophys. Acta Mol. Basis Dis.* 2018, 1864, 2315–2328. [CrossRef]

191. Zemek, R.M.; De Jong, E.; Chin, W.L.; Schuster, I.S.; Fear, V.S.; Casey, T.H.; Forbes, C.; Dart, S.J.; Leslie, C.; Zaitouny, A.; et al. Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment. *Sci. Transl. Med.* 2019, 11. [CrossRef]

192. Lischer, C.; Eberhardt, M.; Jaitly, T.; Schinzel, C.; Schaft, N.; Dorrie, J.; Schuler, G.; Vera, J. Curatopes Melanoma: A Database of Predicted T-cell Epitopes from Overly Expressed Proteins in Metastatic Cutaneous Melanoma. *Cancer Res.* 2019, 79, 5452–5456. [CrossRef] [PubMed]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).